TailorMed agrees sale of control to GrowthCurve in deal valued at about $250 million
Published · Updated
What happened
TailorMed agreed to sell control to U.S. private-equity firm GrowthCurve, with Calcalist valuing the transaction at about $250 million. The reported transaction is expected to leave TailorMed’s Israeli operations continuing after the change in control.
Why it matters
A cross-border control sale in Israeli health-tech provides a current market signal on foreign capital availability, valuation appetite, and ownership turnover in a sector tied to software, healthcare delivery, and data governance. It may also shape expectations for other Israeli private companies weighing fundraising, secondary sales, or relocation of corporate control.
Israeli digital-health company TailorMed agreed to sell control to U.S. private-equity firm GrowthCurve in a transaction that Calcalist valued at about $250 million. The reported plan keeps the company’s Israeli operations in place while shifting control to a foreign financial buyer. For senior economic officials, the deal is a fresh data point on outbound ownership change in Israeli health-tech during a period of political and security volatility.
Watch for
Israeli Competition Authority filing or exemption notice tied to TailorMed or GrowthCurve by 2026-11-06 Israel Innovation Authority statement on TailorMed grant obligations or change-of-control conditions by 2026-11-06 TailorMed or GrowthCurve public announcement naming closing conditions, board changes, or capital injection terms by 2026-11-06 No Companies Authority filing in Israel identifying new controlling shareholders for TailorMed by 2026-11-06
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made